MENLO TIMES

OMass Therapeutics, a biotechnology company developing small molecule therapeutics against highly validated target ecosystems, led by Rosamond Deegan and the team, has announced an oversubscribed $310 million (£230 million) Series C financing round. Proceeds from the financing will support the advancement of the Company’s lead program, OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist, through Phase 2 clinical development in congenital adrenal hyperp

PRIMA, a wireless brain-computer interface implant, is now commercially available in Europe for patients with vision loss caused by geographic atrophy. In a New England Journal of Medicine study, 84% of 32 patients assessed at 12 months reported being able to read letters, numbers, and words. The technology is now being trialled for Stargardt disease and retinitis pigmentosa. In the PRIMAlia trial at Sydney Eye Hospital, the first Stargardt patient received the implant in May

Rivercell, building the AI virtual cell to decipher biology and disease, led by Yann Fleureau and Éric Durand, has announced a $25 million seed round led by HV. HCVC, Alven, and Bpifrance Digital Venture also participated in the round, which will fund the scale-up of Rivercell’s proprietary data generation platform, the expansion of its wet lab in Paris (a lab working with chemicals and biological samples), and the launch of its AI Virtual Cell program. As an indication-agnos

Breye Therapeutics, a clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, led by Ulrik Mouritzen, MD, EMBA, and the team, has raised an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Inno

Basecamp Research, training frontier AI models for therapeutic design, led by Glen Gowers, PhD, Oliver Vince, PhD, and the team, has announced a $140M Series C financing to train a new generation of EDEN models and advance a pipeline of AI-designed therapeutics towards clinical development. The oversubscribed round was led by S32, with participation from Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fu

Dialybrid, developing and commercializing novel arteriovenous vascular grafts for hemodialysis, based on the proprietary innovative technology named Silkothane®, a hybrid material combining silk fibroin and polyurethane, led by Francesco Greco and Stefania A. Riboldi, announced the closing of a €15 million Series A round led by new investor XGEN Venture, with participation of CDP Venture Capital (Rilancio Fund). The financing will support clinical development of Dialybrid’s S

Biolevate, reinventing life sciences operations for the AI era, led by Joel Belafa and the team, announced a €30 million Series A funding round co-led by RAISE France – the investment vehicle of French entrepreneur Aymar Hénin, and Orange Ventures, with participation from MSD Global Health Innovation Fund (MGHIF), Station F, and existing investor EQT Ventures. Biolevate has raised new funding to scale its AI platform for regulated life sciences and expand into the US with a n

Adaptyv Bio, the automated lab for agentic biology, led by Julian Englert and Daniel Nakhaee-Zadeh, has raised a $40M Series A from Highland Europe, Ace Ventures, byFounders, and Y Combinator. Adaptyv is building high-throughput wet-lab infrastructure to enable AI-driven biological research. The company’s work with Anthropic demonstrated a workflow in which Claude designed proteins, sent them to an automated lab, received experimental results, and iterated based on the data.

Xeltis, addressing major life-threatening diseases, backed by Nobel-winning science, led by Eliane Schutte and the team, has raised an additional €20.5M of new funding from new and existing shareholders. Participating investors included the European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita and other current shareholders, alongside Horizon 3 Healthcare, a new investor who led the round. The additional financing, alongside the €50 million secured in

Science Corp, a clinical-stage medical technology company led by Max Hodak and the team, has announced the European commercial launch of PRIMA, the first and only treatment shown in clinical trials to restore functional central vision to patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD), a leading cause of blindness. PRIMA has received a CE (Conformité Européenne) mark under the European Union Medical Device Regulation from DEKRA, authoriz

Chai Discovery, the company engineering AI models to discover new molecules led by Joshua Meier and Matthew McPartlon, has announced a $400M Series C fundraise to further accelerate progress. The round, which values the company at $3.8B, was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension. These firms were joined by new investors Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, Avra Capital, and other nota

Alchemab Therapeutics, pioneering the next generation of antibody therapeutics for hard-to-treat diseases, led by Jane Osbourn, OBE, FMedSci, PhD, and the team, has extended its Series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The funding will enable the company to build its clinical pipeline and grow its proprietary unique antibody dataset to more than a billion sequ

64x Bio, enabling next-generation medicines, Lexi Rovner, PhD, George Church, PhD, David Thompson, PhD, Pamela Silver, PhD, Jeffrey Way, PhD, and the team, has announced the launch of LV Apex Suite, a new product line designed to support high-performance lentiviral vector manufacturing. Platform Expansion. The product launch marks 64x Bio's expansion into lentiviral vector production, extending the capabilities of its VectorSelect platform beyond adeno-associated virus (AAV)

Leyden Labs, freeing humanity from the burden of respiratory viruses, led by Koenraad Wiedhaup, Ronald Brus, and the team, has announced a €40 million investment from the European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio, and others. The Company welcomes Ben Verwaayen as a new Supervisory Board member. Nominated by EIC Fund and Invest-NL, Mr. Verwaayen brings decades of international leadership experience, having served in senior executive and bo

Graph Therapeutics, decoding immune dysfunction at scale, led by Gregory Vladimer, PhD, Robert Sehlke, PhD, Prof. Berend Snijder, PhD, Bojan Vilagos, PhD, and Christophe Boudesco, PhD, has announced that Daphni, the Paris-based venture capital firm, has joined Graph’s investor syndicate to accelerate its internal pipeline. Daphni invests alongside continued participation from existing investors SquareOne, Merantix Capital, and NAVEC Investment Management, with additional non-

Tamarind Bio, building AI infrastructure for biotech R&D, led by Deniz Kavi, Sherry Liu, and the team, is integrating NVIDIA-optimized NIM microservices into the inference layer that powers the Tamarind platform. Building the Infrastructure for Agentic Biology. Advances in AI are rapidly transforming how new molecules, drug candidates, diagnostics, and biological tools are discovered and designed. Yet computational biology workflows often remain complex, requiring researchers

Tamarind Bio, building AI infrastructure for biotech R&D, led by Deniz Kavi, Sherry Liu, and the team, has been selected by Lilly TuneLab as a third-party technology partner to build, host, and operate the inference infrastructure layer for TuneLab2.0, which is now live. Lilly Launches Collaborative AI Drug Discovery Platform. Eli Lilly and Company has introduced Lilly TuneLab, a collaborative AI and machine learning platform designed to accelerate drug discovery across the

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of living drugs, led by Fabian Gerlinghaus and Omar Kurdi, has announced that ARK Invest has joined the company’s Series D financing with a $20 million investment, bringing the total Series D to $277 million. ARK joins a high-caliber group of Cellares investors, including

IMU Biosciences, decoding the immune system with unprecedented resolution and scale to transform how we understand, diagnose, and treat disease, led by Adam Laing, Mario Cantero, John Baker, and Thomas Hayday, has successfully brought its Series A to over $53 million (£40 million) in an oversubscribed financing round, co-led by IQ Capital and Molten Ventures, and supported by The British Business Bank, and Meltwind alongside existing investors. Building a Comprehensive Map o

NewLimit, radically extending human healthspan, led by Jacob Kimmel, Brian Armstrong, Blake Byers, and the team, has closed a $435M Series C led by Founders Fund alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others. The company plans to begin human clinical trials next year following the discovery of a prototype th